FHIR IG analytics
| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113762.1.4.1290.23.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1290.23/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.23 |
| Version | 20250928 |
| Status | active |
| Date | 2025-09-28T01:02:36-04:00 |
| Name | CellBasedGeneTherapiesForSickleCellDisease |
| Title | Cell based gene therapies for sickle cell disease |
| Realm | us |
| Authority | hl7 |
| Description | For MCO reporting using admin data |
| Purpose | (Clinical Focus: Cell-based gene therapies for sickle cell disease (SCD)),(Data Element Scope: Codes to identify therapies which use gene editing or gene addition),(Inclusion Criteria: RxNorm codes to to identify therapies which use gene editing or gene addition),(Exclusion Criteria: none) |
Resources that use this resource
Resources that this resource uses
Narrative
No narrative content found in resource
Source1
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1290.23",
"meta": {
"versionId": "5",
"lastUpdated": "2025-09-28T01:02:36.000-04:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "IPRO Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-09-28"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2025-09-28"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.23",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1290.23"
}
],
"version": "20250928",
"name": "CellBasedGeneTherapiesForSickleCellDisease",
"title": "Cell based gene therapies for sickle cell disease",
"status": "active",
"date": "2025-09-28T01:02:36-04:00",
"publisher": "IPRO Steward",
"description": "For MCO reporting using admin data",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: Cell-based gene therapies for sickle cell disease (SCD)),(Data Element Scope: Codes to identify therapies which use gene editing or gene addition),(Inclusion Criteria: RxNorm codes to to identify therapies which use gene editing or gene addition),(Exclusion Criteria: none)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "2672689",
"display": "lovotibeglogene autotemcel Injectable Product"
},
{
"code": "2672691",
"display": "20 ML lovotibeglogene autotemcel 20000000 CELLS/ML Injection"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:d8210aed-538a-4cc1-88aa-cd22263a81cd",
"timestamp": "2025-11-24T16:58:44-05:00",
"total": 2,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "09022025",
"code": "2672689",
"display": "lovotibeglogene autotemcel Injectable Product"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "09022025",
"code": "2672691",
"display": "20 ML lovotibeglogene autotemcel 20000000 CELLS/ML Injection"
}
]
}
}